Hennion & Walsh Asset Management Inc. Increases Stock Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Hennion & Walsh Asset Management Inc. boosted its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 18.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 863,255 shares of the biopharmaceutical company’s stock after acquiring an additional 132,117 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.35% of Lexicon Pharmaceuticals worth $638,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. CVI Holdings LLC acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at $34,000. Great Point Partners LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth $50,000. BNP Paribas Financial Markets raised its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,246 shares during the period. SG Americas Securities LLC raised its holdings in shares of Lexicon Pharmaceuticals by 107.6% during the third quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 23,893 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 13,972 shares during the period. 74.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LXRX. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Stock Down 3.3 %

Lexicon Pharmaceuticals stock opened at $0.69 on Tuesday. The company has a 50-day simple moving average of $0.81 and a 200-day simple moving average of $1.42. The firm has a market capitalization of $169.91 million, a P/E ratio of -0.92 and a beta of 1.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals, Inc. has a one year low of $0.62 and a one year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same quarter in the prior year, the company posted ($0.21) EPS. As a group, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.